Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Rob Jones

Biogen Idec building

FDA starts review of Biogen’s Tecfidera follow-up for MS

It was initally submitted towards the end of 2018 but had been delayed by US gov shutdown

- PMLiVE

Senate grilling makes pharma CEOs squirm, but give little ground

Some signal willingness to compromise, but oppose most radical reforms

Celgene building

FDA begins speedy review of Celgene’s Revlimid combo in lymphoma

R2 met its primary endpoint of PFS in trials

- PMLiVE

AZ says Brilinta hits the mark in diabetic heart disease

The drug can reduce cardiovascular events in diabetics with CAD

- PMLiVE

Pharma industry swamped with no-deal Brexit info, says BIA

Deluge comes just as prime minister hints at delay

Visualising medicine

How creative can simplify the complex

- PMLiVE

Fireworks likely at Senate drug pricing hearing today

Senators fire broadsides: "I hope CEOs don't blame everyone but themselves"

- PMLiVE

Novartis and Syncona back new Swiss biotech Anaveon

Founders focused on IL-2 Receptor Agonists

- PMLiVE

FDA and Flatiron extend real world evidence collaboration

Roche-owned specialists at forefront of big data analysis

- PMLiVE

Lynparza scores against pancreatic cancer

AZ and MSD drug success in BRCA-mutated disease

- PMLiVE

Q&A: Nicola Walsby

Gemma Jones interviews Syneos Health's Managing Director PR UK

Doctors Letter

Health Literacy in Practice: Doctor’s Letter

If a patient was given their results directly, how could we make it into something they could understand and, most importantly, act on?

Cuttsy + Cuttsy

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links